Literature DB >> 11063496

Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies.

B Ohana1, M Lipson, N Vered, I Srugo, M Ahdut, A Morag.   

Abstract

Recently a few new herpes simplex virus (HSV) type-specific serological diagnostic tests have been introduced to the commercial market, but these tests have some limitations. Moreover, it is not yet clear which commercial test can be regarded as a "gold standard" for the serodiagnosis of HSV infections. In order to improve the clinical diagnostic value of serological tests for the detection of HSV infections, we developed novel, competition-based enzyme-linked immunosorbent assays for the specific determination of HSV type 2 antibodies (SeroHSV2) and HSV type 1 antibodies (SeroHSV1) and two complementary tests for the detection of HSV immunoglobulin M (IgM) and IgG antibodies (SeroHSV IgM and SeroHSV IgG). These four new kits were evaluated in comparison with some commercial kits for the detection of HSV antibodies that are commonly used at present in Israeli clinical laboratories. The results indicate that SeroHSV2 is highly sensitive (>92%) and highly specific (>94%). SeroHSV2 does not cross-react with other alphaherpesvirus antibodies. SeroHSV1 is highly sensitive (>94%) and specific (>91%) compared to four commercial available kits. SeroHSV IgM is highly specific (>92%) in comparison with other commercial HSV IgM tests. The sensitivity of SeroHSV IgM ranges between 50 and 70% compared to these tests. Further investigation of the discrepant results obtained by using in-house competition tests indicated that SeroHSV IgM is more sensitive. SeroHSV IgG was also found to be highly sensitive (>94%) and highly specific (>92%) compared to the other commercial HSV IgG tests.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063496      PMCID: PMC95983          DOI: 10.1128/CDLI.7.6.904-908.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  13 in total

1.  Herpes simplex virus type 2 in the United States, 1976 to 1994.

Authors:  D T Fleming; G M McQuillan; R E Johnson; A J Nahmias; S O Aral; F K Lee; M E St Louis
Journal:  N Engl J Med       Date:  1997-10-16       Impact factor: 91.245

Review 2.  Infections with herpes simplex viruses (1).

Authors:  L Corey; P G Spear
Journal:  N Engl J Med       Date:  1986-03-13       Impact factor: 91.245

3.  Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera.

Authors:  A M Eis-Hübinger; M Däumer; B Matz; K E Schneweis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 4.  The current trend in genital herpes. Progress in prevention.

Authors:  L Corey
Journal:  Sex Transm Dis       Date:  1994 Mar-Apr       Impact factor: 2.830

5.  Comparison of a monoclonal antibody-blocking enzyme-linked immunoassay and a strip immunoblot assay for identifying type-specific herpes simplex virus type 2 serological responses.

Authors:  G J Van Doornum; M J Slomka; M Buimer; J Groen; J A Van den Hoek; I Cairo; A Vyse; D W Brown
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

6.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

7.  The acquisition of herpes simplex virus during pregnancy.

Authors:  Z A Brown; S Selke; J Zeh; J Kopelman; A Maslow; R L Ashley; D H Watts; S Berry; M Herd; L Corey
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245

8.  Recurrence rates in genital herpes after symptomatic first-episode infection.

Authors:  J Benedetti; L Corey; R Ashley
Journal:  Ann Intern Med       Date:  1994-12-01       Impact factor: 25.391

9.  Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay.

Authors:  M J Slomka; R L Ashley; F M Cowan; A Cross; D W Brown
Journal:  J Virol Methods       Date:  1995-09       Impact factor: 2.014

10.  The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991.

Authors:  J D Ross; I W Smith; R A Elton
Journal:  Genitourin Med       Date:  1993-10
View more
  5 in total

Review 1.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

2.  High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients.

Authors:  Laurent Andréoletti; Emmanuel Piednoir; Jérôme Legoff; Véronique Brodard; Isabelle Beguinot; Christophe Strady; Christine Rouger; Christophe Piketty; Ali Si-Mohamed; Michel Daniel Kazatchkine; Jean-Elie Malkin; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.

Authors:  Catherine Féart; Catherine Helmer; Hervé Fleury; Yannick Béjot; Karen Ritchie; Philippe Amouyel; Susanna Schraen-Maschke; Luc Buée; Jean-Charles Lambert; Luc Letenneur; Jean-François Dartigues
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

4.  Analysis of human papillomavirus and herpes simplex virus genus -2 from patients with cervical cancer in isfahan, iran.

Authors:  Mehrnaz Shanehsazzadeh; Javad Sharifi-Rad; Mandana Behbahani; Abbasali Pourazar
Journal:  Mater Sociomed       Date:  2014-08-26

5.  SERO-prevalence of herpes simplex virus type 1 and type 2 among women attending routine Cervicare clinics in Ghana.

Authors:  Oksana Debrah; Francis Agyemang-Yeboah; Richard Harry Asmah; Emmanuel Timmy-Donkoh; Mohammed Mustapha Seini; Linda Ahenkorah Fondjo; Nilok Sight; Ellis Owusu-Dabo
Journal:  BMC Infect Dis       Date:  2018-08-07       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.